{"transactions":[{"id":4628950,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:54:38.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":2189,"price":8.676,"value":18991.764,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":2189,"derivative":{"exercise_price":10.44,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":2189},"source":{"system":"sec-edgar","filing":"0001193125-26-412654","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526412654/ownership.xml","form_type":"4"}},{"id":721152,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:21:13.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":2199,"price":8.639,"value":18997.161,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":2199,"derivative":{"exercise_price":10.3,"exercise_date":"2026-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":2199},"source":{"system":"sec-edgar","filing":"0001494695-26-000018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000018/ownership.xml","form_type":"4"}},{"id":727605,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:26:36.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001494695-26-000015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000015/ownership.xml","form_type":"4"}},{"id":732045,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:15:23.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":5882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant."}],"balance_after":475465,"source":{"system":"sec-edgar","filing":"0001494695-26-000013","document":"form4-06182026_040618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000013/form4-06182026_040618.xml","form_type":"4"}},{"id":746128,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:41:08.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":12610,"price":64.42,"value":812336.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.27 to $64.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by the Paul B. Manning Revocable Trust (the \"PBM 2000 Trust\"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust."}],"balance_after":798335,"source":{"system":"sec-edgar","filing":"0001494695-26-000011","document":"form4-06082026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000011/form4-06082026_080604.xml","form_type":"4"}},{"id":746127,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:41:08.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":68265,"price":63.83,"value":4357354.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.27 to $64.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by the Paul B. Manning Revocable Trust (the \"PBM 2000 Trust\"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust."}],"balance_after":810945,"source":{"system":"sec-edgar","filing":"0001494695-26-000011","document":"form4-06082026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000011/form4-06082026_080604.xml","form_type":"4"}},{"id":746126,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:41:08.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":19125,"price":62.62,"value":1197607.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.21 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by the Paul B. Manning Revocable Trust (the \"PBM 2000 Trust\"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust."}],"balance_after":879210,"source":{"system":"sec-edgar","filing":"0001494695-26-000011","document":"form4-06082026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000011/form4-06082026_080604.xml","form_type":"4"}},{"id":746125,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:41:08.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":88487,"price":64.28,"value":5687944.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":716311,"source":{"system":"sec-edgar","filing":"0001494695-26-000011","document":"form4-06082026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000011/form4-06082026_080604.xml","form_type":"4"}},{"id":746124,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:41:08.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":11513,"price":63.13,"value":726815.69,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.365 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":804798,"source":{"system":"sec-edgar","filing":"0001494695-26-000011","document":"form4-06082026_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000011/form4-06082026_080604.xml","form_type":"4"}},{"id":819482,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T21:17:15.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":4618,"price":4.114,"value":18998.452,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":4618,"derivative":{"exercise_price":4.9,"exercise_date":"2026-04-01","expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":4618},"source":{"system":"sec-edgar","filing":"0001494695-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000007/ownership.xml","form_type":"4"}},{"id":879577,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T00:38:59.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":550458,"price":5.45,"value":2999996.1,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2763527,"source":{"system":"sec-edgar","filing":"0001193125-26-078246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000119312526078246/ownership.xml","form_type":"4"}},{"id":907537,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:16:26.000Z","date":"2026-02-11","kind":"other","planned":false,"acquired":true,"shares":55116,"price":42.63,"value":2349595.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 375,712 shares distributed to the Reporting Person in satisfaction of annuity obligation from the PBM 2024 GRAT."}],"balance_after":469583,"source":{"system":"sec-edgar","filing":"0001494695-26-000002","document":"form4-02132026_020223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000002/form4-02132026_020223.xml","form_type":"4"}},{"id":907536,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:16:26.000Z","date":"2026-02-11","kind":"other","planned":false,"acquired":false,"shares":55116,"price":42.63,"value":2349595.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the PBM 2024 GRAT. The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001494695-26-000002","document":"form4-02132026_020223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000002/form4-02132026_020223.xml","form_type":"4"}},{"id":988672,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":687690,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":687690,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":687690},"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988671,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":343845,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":343845,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":343845},"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988670,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":2750762,"price":4.2425,"value":11670107.785,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":3348372,"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988669,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":1375380,"price":4.2425,"value":5835049.65,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":3958189,"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":1051406,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:46:13.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":74230,"price":29.14,"value":2163062.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.25 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT."}],"balance_after":430828,"source":{"system":"sec-edgar","filing":"0001415889-25-023468","document":"form4-09022025_110909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000141588925023468/form4-09022025_110909.xml","form_type":"4"}},{"id":1051405,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:46:13.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":254038,"price":28.67,"value":7283269.46,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $29.065 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT."}],"balance_after":505058,"source":{"system":"sec-edgar","filing":"0001415889-25-023468","document":"form4-09022025_110909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000141588925023468/form4-09022025_110909.xml","form_type":"4"}},{"id":1051404,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:46:13.000Z","date":"2025-08-29","kind":"sale","planned":false,"acquired":false,"shares":188232,"price":27.62,"value":5198967.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.77 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT."}],"balance_after":759096,"source":{"system":"sec-edgar","filing":"0001415889-25-023468","document":"form4-09022025_110909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000141588925023468/form4-09022025_110909.xml","form_type":"4"}},{"id":1051403,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-02T23:46:13.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":154337,"price":27.94,"value":4312175.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the \"PBM 2024 GRAT\"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT."}],"balance_after":947328,"source":{"system":"sec-edgar","filing":"0001415889-25-023468","document":"form4-09022025_110909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000141588925023468/form4-09022025_110909.xml","form_type":"4"}},{"id":1101047,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:10.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":1070663,"price":4.67,"value":4999996.21,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2213069,"source":{"system":"sec-edgar","filing":"0000950170-25-090197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017025090197/ownership.xml","form_type":"4"}},{"id":1104980,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:32:36.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":18396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant."}],"balance_after":38755,"source":{"system":"sec-edgar","filing":"0001104659-25-061191","document":"tm2518541-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465925061191/tm2518541-5_4seq1.xml","form_type":"4"}},{"id":1106240,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:35:33.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017025087702/ownership.xml","form_type":"4"}},{"id":1126544,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T01:38:27.000Z","date":"2025-05-30","kind":"purchase","planned":false,"acquired":true,"shares":750000,"price":2.75,"value":2062500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2841704,"source":{"system":"sec-edgar","filing":"0001415889-25-015480","document":"form4-06042025_010624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015480/form4-06042025_010624.xml","form_type":"4"}},{"id":1326628,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T21:11:47.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":750000,"price":6,"value":4500000.0,"ownership":{"direct":false,"nature":"By BKB Growth Investments, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":1303752,"source":{"system":"sec-edgar","filing":"0000950170-24-137889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017024137889/ownership.xml","form_type":"4"}},{"id":1326627,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T21:11:47.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":6,"value":3000000.0,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":1142406,"source":{"system":"sec-edgar","filing":"0000950170-24-137889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017024137889/ownership.xml","form_type":"4"}},{"id":1350926,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2247191,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2247191,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":2247191},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350925,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2247191,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2247191,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":2247191},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350924,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":9213483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":9213483,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":9213483},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350923,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":9213483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":9213483,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":9213483},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350922,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":25828094,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350921,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":4494382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":5976101,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350920,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":18426966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":26278094,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1400884,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.42,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.42,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400883,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.42,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.42,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400882,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.41,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.41,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400881,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":false,"shares":2675611.25,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1406613,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:05:20.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":337078,"price":8.9,"value":2999994.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's underwritten public offering of common stock, which closed on September 12, 2024, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc., pursuant to which the shares cannot be sold for 90 days following September 11, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":816311,"source":{"system":"sec-edgar","filing":"0001104659-24-100179","document":"tm2424167-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465924100179/tm2424167-1_4seq1.xml","form_type":"4"}},{"id":1466672,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-01T12:00:07.000Z","date":"2024-06-27","kind":"purchase","planned":false,"acquired":true,"shares":1333333,"price":2.25,"value":2999999.25,"ownership":{"direct":true},"balance_after":1333333,"source":{"system":"sec-edgar","filing":"0001415889-24-018515","document":"form4-07012024_080703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924018515/form4-07012024_080703.xml","form_type":"4"}},{"id":1468102,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T12:37:28.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":5.71,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-24-078171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017024078171/ownership.xml","form_type":"4"}},{"id":1470642,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T01:39:28.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant."}],"balance_after":299689,"source":{"system":"sec-edgar","filing":"0001104659-24-074473","document":"tm2418154-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465924074473/tm2418154-6_4seq1.xml","form_type":"4"}},{"id":1707149,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T22:00:54.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":279330,"price":7.16,"value":2000002.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's underwritten public offering of common stock, which closed on December 14, 2023, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc.., pursuant to which the shares cannot be sold for 90 days following December 12, 2023."}],"balance_after":279330,"source":{"system":"sec-edgar","filing":"0001104659-23-126932","document":"tm2332275-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465923126932/tm2332275-6_4seq1.xml","form_type":"4"}},{"id":1735480,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-20T12:35:02.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.63,"value":163000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Revocable Trust\"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust."}],"balance_after":16566667,"source":{"system":"sec-edgar","filing":"0001209191-23-055942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123055942/doc4.xml","form_type":"4"}},{"id":1806746,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T00:57:08.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":16466667,"price":0.9,"value":14820000.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Revocable Trust\"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust."}],"balance_after":16466667,"source":{"system":"sec-edgar","filing":"0001209191-23-046154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046154/doc4.xml","form_type":"4"}},{"id":1824144,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T22:47:54.000Z","date":"2023-07-24","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":5.02,"value":1004000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price\nwithin the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust.  This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":7851128,"source":{"system":"sec-edgar","filing":"0001209191-23-043255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919123043255/doc4.xml","form_type":"4"}},{"id":1841976,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-29T13:00:15.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":1.22,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0001209191-23-040134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919123040134/doc4.xml","form_type":"4"}},{"id":1847788,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-21T21:01:37.000Z","date":"2023-06-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments and will become fully vested on June 19, 2026."}],"balance_after":20000,"derivative":{"exercise_price":8.63,"exercise_date":"2026-06-19","expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-23-073393","document":"tm2317720-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465923073393/tm2317720-7_4seq1.xml","form_type":"4"}},{"id":2127789,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-02T20:09:10.000Z","date":"2022-10-31","kind":"purchase","acquired":true,"shares":1500000,"price":2,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of 1,500,000 shares of common stock held by Mr. Manning and 142,202 shares of common stock held by Mr. Manning jointly with his spouse."}],"balance_after":1642202,"source":{"system":"sec-edgar","filing":"0001209191-22-055263","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122055263/doc4.xml","form_type":"4"}},{"id":2136311,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-17T20:36:03.000Z","date":"2022-10-13","kind":"grant","acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) October 13, 2023 or (ii) the date of the next Annual Meeting of Stockholders of the Company; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Company or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":2.81,"expiration_date":"2032-10-13","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0001209191-22-053828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919122053828/doc4.xml","form_type":"4"}},{"id":2214693,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T20:10:11.000Z","date":"2022-07-05","kind":"purchase","acquired":true,"shares":4761904,"price":2.1,"value":9999998.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":13651128,"source":{"system":"sec-edgar","filing":"0001209191-22-040581","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919122040581/doc4.xml","form_type":"4"}},{"id":2224672,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T20:36:06.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":2.81,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-038685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122038685/doc4.xml","form_type":"4"}},{"id":2224133,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-22T20:31:25.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments and will become fully vested on June 17, 2025."}],"balance_after":20000,"derivative":{"exercise_price":4.86,"exercise_date":"2025-06-17","expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-073527","document":"tm2219055-3_4seq.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465922073527/tm2219055-3_4seq.xml","form_type":"4"}},{"id":2293887,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-20T20:36:37.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":435674,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 31, 2022, 435,674 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC (\"RareGen\") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by PBM Capital Finance, LLC (\"PBM\"). The Reporting Person is the manager and sole beneficial owner of PBM."}],"balance_after":435674,"source":{"system":"sec-edgar","filing":"0001104659-22-047871","document":"tm2213052-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465922047871/tm2213052-4_4seq1.xml","form_type":"4"}},{"id":2294777,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-19T20:30:32.000Z","date":"2022-04-18","kind":"purchase","acquired":true,"shares":392156,"price":5.1,"value":1999995.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on April 18, 2022, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc.., pursuant to which the shares cannot be sold for 90 days following April 12, 2022."}],"balance_after":392156,"source":{"system":"sec-edgar","filing":"0001104659-22-047360","document":"tm2213052-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465922047360/tm2213052-1_4seq1.xml","form_type":"4"}},{"id":2397899,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:16:56.000Z","date":"2021-09-07","kind":"gift","acquired":true,"shares":4460308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares of are held by Reporting Person jointly with his spouse."}],"balance_after":4460308,"source":{"system":"sec-edgar","filing":"0001209191-22-009600","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919122009600/doc5.xml","form_type":"5"}},{"id":2397898,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:16:56.000Z","date":"2021-09-07","kind":"gift","acquired":false,"shares":4460308,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by PD Joint Holdings, LLC Series 2016-A (\"PD\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD."}],"balance_after":198413,"source":{"system":"sec-edgar","filing":"0001209191-22-009600","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919122009600/doc5.xml","form_type":"5"}},{"id":2397897,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:16:56.000Z","date":"2021-07-06","kind":"gift","acquired":true,"shares":3921075,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by PD Joint Holdings, LLC Series 2016-A (\"PD\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD."}],"balance_after":4658721,"source":{"system":"sec-edgar","filing":"0001209191-22-009600","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919122009600/doc5.xml","form_type":"5"}},{"id":2397896,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:16:56.000Z","date":"2021-07-06","kind":"gift","acquired":false,"shares":3921075,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by PBM Capital Finance, LLC (\"PBM\"). The Reporting Person is the manager and sole beneficial owner of PBM."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-009600","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919122009600/doc5.xml","form_type":"5"}},{"id":2398012,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:15:40.000Z","date":"2021-07-06","kind":"gift","acquired":true,"shares":739830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Consists of 7,754,783 shares of common stock held by Mr. Manning and 1,134,441 shares of common stock held by Mr. Manning jointly with his spouse."}],"balance_after":8889224,"source":{"system":"sec-edgar","filing":"0001209191-22-009596","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919122009596/doc5.xml","form_type":"5"}},{"id":2398011,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T02:15:40.000Z","date":"2021-07-06","kind":"gift","acquired":false,"shares":739830,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-009596","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919122009596/doc5.xml","form_type":"5"}},{"id":2397892,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T21:37:47.000Z","date":"2021-07-14","kind":"gift","acquired":false,"shares":36752,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":642406,"source":{"system":"sec-edgar","filing":"0000899243-22-006184","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924322006184/doc5.xml","form_type":"5"}},{"id":2412331,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T13:28:06.000Z","date":"2022-02-03","kind":"purchase","acquired":true,"shares":26602,"price":7.84,"value":208559.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.725 to $8.00 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2091704,"source":{"system":"sec-edgar","filing":"0001209191-22-007126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122007126/doc4.xml","form_type":"4"}},{"id":2412330,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T13:28:06.000Z","date":"2022-02-03","kind":"purchase","acquired":true,"shares":50000,"price":7.84,"value":392000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.725 to $8.00 inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Mr. Manning jointly with his spouse."}],"balance_after":142202,"source":{"system":"sec-edgar","filing":"0001209191-22-007126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122007126/doc4.xml","form_type":"4"}},{"id":2412329,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T13:28:06.000Z","date":"2022-02-02","kind":"purchase","acquired":true,"shares":22000,"price":7.77,"value":170940.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB G2 Investments LLC (\"BKB G2\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001209191-22-007126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122007126/doc4.xml","form_type":"4"}},{"id":2412328,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T13:28:06.000Z","date":"2022-02-02","kind":"purchase","acquired":true,"shares":45000,"price":7.77,"value":349650.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2065102,"source":{"system":"sec-edgar","filing":"0001209191-22-007126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122007126/doc4.xml","form_type":"4"}},{"id":2412327,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T13:28:06.000Z","date":"2022-02-02","kind":"purchase","acquired":true,"shares":58000,"price":7.77,"value":450660.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Mr. Manning jointly with his spouse."}],"balance_after":92202,"source":{"system":"sec-edgar","filing":"0001209191-22-007126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122007126/doc4.xml","form_type":"4"}},{"id":2483776,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-06T13:20:22.000Z","date":"2021-12-03","kind":"purchase","acquired":true,"shares":19977,"price":9.22,"value":184187.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $9.77 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Consists of 7,754,783 shares of common stock held by Mr. Manning and 394,611 shares of common stock held by Mr. Manning jointly with his\nspouse."}],"balance_after":8149394,"source":{"system":"sec-edgar","filing":"0001209191-21-068031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919121068031/doc4.xml","form_type":"4"}},{"id":2483775,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-06T13:20:22.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":30023,"price":9.45,"value":283717.35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.335 to $9.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 7,754,783 shares of common stock held by Mr. Manning and 374,634\nshares of common stock held by Mr. Manning jointly with his spouse."}],"balance_after":8129417,"source":{"system":"sec-edgar","filing":"0001209191-21-068031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919121068031/doc4.xml","form_type":"4"}},{"id":2493807,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-29T22:01:55.000Z","date":"2021-11-24","kind":"purchase","acquired":true,"shares":2202,"price":13.19,"value":29044.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.115 to $13.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Mr. Manning jointly with his spouse."}],"balance_after":34202,"source":{"system":"sec-edgar","filing":"0001209191-21-067005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121067005/doc4.xml","form_type":"4"}},{"id":2496730,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T12:58:36.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":20000,"price":12.54,"value":250800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.10 to $12.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Mr. Manning jointly with his spouse."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001209191-21-066702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121066702/doc4.xml","form_type":"4"}},{"id":2583471,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-09-01T21:24:18.000Z","date":"2021-08-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024."}],"balance_after":20000,"derivative":{"exercise_price":2.59,"exercise_date":"2024-08-20","expiration_date":"2031-08-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-21-112108","document":"tm2126786-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465921112108/tm2126786-6_4seq1.xml","form_type":"4"}},{"id":2614817,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-04T20:41:14.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":1361069,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By BKB Growth Investments, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":553752},"source":{"system":"sec-edgar","filing":"0000899243-21-031614","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031614/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-02"}},{"id":2614816,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-04T20:41:14.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":1669303,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":679158},"source":{"system":"sec-edgar","filing":"0000899243-21-031614","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031614/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-02"}},{"id":2614815,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T20:41:14.000Z","date":"2021-07-29","kind":"purchase","acquired":true,"shares":1625000,"price":8,"value":13000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Includes shares held jointly with spouse."}],"balance_after":1681000,"source":{"system":"sec-edgar","filing":"0000899243-21-031614","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031614/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-02"}},{"id":2614814,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T20:41:14.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":553752,"ownership":{"direct":false,"nature":"By BKB Growth Investments, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":553752,"source":{"system":"sec-edgar","filing":"0000899243-21-031614","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031614/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-02"}},{"id":2614813,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T20:41:14.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":679158,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":679158,"source":{"system":"sec-edgar","filing":"0000899243-21-031614","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031614/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-02"}},{"id":2619984,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-03T00:08:31.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":1361069,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By BKB Growth Investments, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":553752},"source":{"system":"sec-edgar","filing":"0000899243-21-031096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031096/doc4.xml","form_type":"4"}},{"id":2619983,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-03T00:08:31.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":1669303,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":679158},"source":{"system":"sec-edgar","filing":"0000899243-21-031096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031096/doc4.xml","form_type":"4"}},{"id":2619982,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T00:08:31.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":553752,"ownership":{"direct":false,"nature":"By BKB Growth Investments, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":553752,"source":{"system":"sec-edgar","filing":"0000899243-21-031096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031096/doc4.xml","form_type":"4"}},{"id":2619981,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T00:08:31.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":679158,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":679158,"source":{"system":"sec-edgar","filing":"0000899243-21-031096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321031096/doc4.xml","form_type":"4"}},{"id":2622124,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-30T01:02:52.000Z","date":"2021-07-29","kind":"purchase","acquired":true,"shares":20000,"price":7.2972,"value":145944.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.855 to $7.80. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held jointly with spouse."}],"balance_after":56000,"source":{"system":"sec-edgar","filing":"0000899243-21-030774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321030774/doc4.xml","form_type":"4"}},{"id":2622123,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-30T01:02:52.000Z","date":"2021-07-27","kind":"purchase","acquired":true,"shares":36000,"price":7.3565,"value":264834.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.31 to $7.40. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held jointly with spouse."}],"balance_after":36000,"source":{"system":"sec-edgar","filing":"0000899243-21-030774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000089924321030774/doc4.xml","form_type":"4"}},{"id":2638047,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":657985,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the\nmanager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":657985},"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2638046,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":1315969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1315969},"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2638045,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":1634515,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1634515},"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2638044,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":657985,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the\nmanager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":657985,"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2638043,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":3352693,"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2638042,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-08T22:35:25.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":2950484,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred\nStock\") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of\nthe Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":3040193,"source":{"system":"sec-edgar","filing":"0001209191-21-046042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000120919121046042/doc4.xml","form_type":"4"}},{"id":2662321,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T20:59:35.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":25.04,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-21-042087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121042087/doc4.xml","form_type":"4"}},{"id":2711323,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:48:34.000Z","date":"2021-05-14","kind":"purchase","acquired":true,"shares":12000,"price":20.98,"value":251760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.81 to $21.225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this\nfootnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Mr. Manning jointly with his spouse."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-21-033009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121033009/doc4.xml","form_type":"4"}},{"id":2748588,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T13:24:04.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":198413,"price":2.52,"value":500000.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by PD Joint Holdings, LLC Series 2016-A (\"PD\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC (\"Tiger Lily\"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD."}],"balance_after":737646,"source":{"system":"sec-edgar","filing":"0001104659-21-050550","document":"tm2113044-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465921050550/tm2113044-2_4seq1.xml","form_type":"4"}},{"id":2769306,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-29T13:12:11.000Z","date":"2021-03-25","kind":"purchase","acquired":true,"shares":739830,"price":14.75,"value":10912492.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":739830,"source":{"system":"sec-edgar","filing":"0001209191-21-023388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919121023388/doc4.xml","form_type":"4"}},{"id":2770575,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-03-26T20:07:49.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":21385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021."}],"balance_after":21385,"derivative":{"exercise_price":2.51,"expiration_date":"2031-03-24","underlying":"Common Stock","underlying_shares":21385},"source":{"system":"sec-edgar","filing":"0001104659-21-042434","document":"tm2111007-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465921042434/tm2111007-5_4seq1.xml","form_type":"4"}},{"id":2860877,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:45:53.000Z","date":"2020-12-31","kind":"gift","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":3195205,"source":{"system":"sec-edgar","filing":"0001209191-21-010878","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121010878/doc5.xml","form_type":"5"}},{"id":2973147,"issuer":{"id":1860,"kind":"organization","name":"Liquidia Corp","symbol":"LQDA"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-11-19T21:10:43.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments, becoming fully vested on November 18, 2023."}],"balance_after":30000,"derivative":{"exercise_price":3.38,"expiration_date":"2030-11-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-20-127348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000110465920127348/a4.xml","form_type":"4"}},{"id":3020350,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-30T20:37:04.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":10963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11944},"source":{"system":"sec-edgar","filing":"0001209191-20-052459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052459/doc4.xml","form_type":"4"}},{"id":3020349,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T20:37:04.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":1843193,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2008158},"source":{"system":"sec-edgar","filing":"0001209191-20-052459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052459/doc4.xml","form_type":"4"}},{"id":3020348,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T20:37:04.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":3006155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the\nTrust and has sole voting and investment power with respect to the shares held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3275205},"source":{"system":"sec-edgar","filing":"0001209191-20-052459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052459/doc4.xml","form_type":"4"}},{"id":3020347,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T20:37:04.000Z","date":"2020-09-28","kind":"exercise","acquired":true,"shares":11944,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2020102,"source":{"system":"sec-edgar","filing":"0001209191-20-052459","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052459/doc4.xml","form_type":"4"}}],"next_cursor":"2020-09-30T20:37:04.000000Z,3020347"}